

144/A: Filer Information

Filer CIK	0002034802
Filer CCC	XXXXXXXX
Previous Accession Number Of The Filing	0001971857-25-000001
Is this a LIVE or TEST Filing?	<input checked="" type="radio"/> LIVE <input type="radio"/> TEST

Submission Contact Information

Name	
Phone	
E-Mail Address	

144/A: Issuer Information

Name of Issuer	Sonoma Pharmaceuticals, Inc.
SEC File Number	001-33216
Address of Issuer	5445 CONESTOGA COURT, SUITE 150 BOULDER COLORADO 80301
Phone	800-759-9305
Name of Person for Whose Account the Securities are To Be Sold	Gottfurcht Grant

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer	10% Stockholder
------------------------	-----------------

144/A: Securities Information

Title of the Class of Securities To Be Sold	Common
Name and Address of the Broker	Merrill Lynch 1500 American Blvd NJ2-150-02-40 Pennington NJ 08534
Number of Shares or Other Units To Be Sold	17806
Aggregate Market Value	48562.46
Number of Shares or Other Units Outstanding	1339170
Approximate Date of Sale	12/31/2024
Name the Securities Exchange	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144/A: Securities To Be Sold

Title of the Class	COMMON
Date you Acquired	06/27/2024
Nature of Acquisition Transaction	Open Market
Name of Person from Whom Acquired	Grant Gottfurcht

Is this a Gift?	<input type="checkbox"/> Date Donor Acquired	
-----------------	--	--

Amount of Securities Acquired	881000
Date of Payment	06/27/2024
Nature of Payment	CASH

If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144/A: Securities Sold During The Past 3 Months

Nothing to Report	<input checked="" type="checkbox"/>
-------------------	-------------------------------------

144/A: Remarks and Signature

Remarks	Amendment to signature page of original filing on 1/02/2025 Amendment to acquisition amount to reflect pre-split qty
Date of Notice	01/02/2025

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature	Grant Gottfurcht
-----------	------------------

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)